Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer
- PMID: 23945384
- DOI: 10.1097/JTO.0b013e31829f684a
Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer
Abstract
Background: This study investigated whether there were differential survival outcomes to first-line tyrosine kinase inhibitors (TKI) in patients with metastatic non-small-cell lung cancer harboring different subtypes of exon 19 and exon 21 mutations on epidermal growth factor receptor (EGFR).
Methods: Of 452 patients with stage IIIB and IV non-small-cell lung cancer, 192 patients (42.5%) harbored EGFR mutation and 170 (37.5%) received TKI as first-line treatment. EGFR mutation analysis was performed by direct sequencing. Survival and response outcome were compared among different subtypes of exon 19 and exon 21 EGFR mutations in these 170 patients.
Results: Patients harboring exon 19 18-nucleotide deletion (delL747_P753insS) had the shortest median progression-free survival (PFS) (6.5 months), followed by those with 15-nucleotide deletion (delE746_A750) (12.4 months) and mixed insertion/substitution mutations (22.3 months; p = 0.012). However, patients who had exon 19 deletions starting on codon E746 had better median PFS (14.2 months) than those starting on L747 (6.5 months; hazard ratio, 0.445; 95% confidence interval [0.219-0.903]; p = 0.021). Besides, exon 21 L858R derived a longer median PFS than L861R/L861Q (11.4 months versus 2.1 months, respectively; hazard ratio, 0.298; 95% confidence interval [0.090-0.980]; p = 0.034).
Conclusions: Different subtypes of EGFR exon 19 and 21 mutations exhibited differential survival to first-line TKI therapy. Detailed sequence evaluation of exon 19 deletions may provide important prognostic information on survival outcome after TKI.
Similar articles
-
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. J Thorac Oncol. 2014. PMID: 24736073
-
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.Lung Cancer. 2014 Nov;86(2):213-8. doi: 10.1016/j.lungcan.2014.09.014. Epub 2014 Sep 22. Lung Cancer. 2014. PMID: 25304185
-
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5. J Thorac Oncol. 2012. PMID: 22982650
-
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.Lung Cancer. 2022 Apr;166:9-16. doi: 10.1016/j.lungcan.2022.01.014. Epub 2022 Jan 25. Lung Cancer. 2022. PMID: 35151115 Review.
-
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.BMC Cancer. 2018 Feb 6;18(1):148. doi: 10.1186/s12885-018-4075-5. BMC Cancer. 2018. PMID: 29409466 Free PMC article. Review.
Cited by
-
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants.JTO Clin Res Rep. 2023 Dec 19;5(2):100624. doi: 10.1016/j.jtocrr.2023.100624. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38304857 Free PMC article.
-
Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.BMC Cancer. 2024 Jan 12;24(1):70. doi: 10.1186/s12885-023-11782-6. BMC Cancer. 2024. PMID: 38216948 Free PMC article.
-
The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.Transl Lung Cancer Res. 2023 Sep 28;12(9):1896-1911. doi: 10.21037/tlcr-23-118. Epub 2023 Aug 23. Transl Lung Cancer Res. 2023. PMID: 37854154 Free PMC article.
-
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497. Clin Cancer Res. 2023. PMID: 36913537 Free PMC article.
-
Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review.Transl Cancer Res. 2022 Oct;11(10):3895-3902. doi: 10.21037/tcr-22-1050. Transl Cancer Res. 2022. PMID: 36388025 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous